NCT00969410
- Conditions
- Digestive System Diseases, Digestive System Neoplasms, Liver Diseases, +9 more
- Locations
-
- Investigational Site 1 Barcelona, Spain
Clinical trial condition
Neoplasms by Site
Explore clinical trials studying Neoplasms by Site. Study availability and eligibility vary by location and protocol.
138 public trials
42 recruiting studies
Neoplasms by Site trial results
Completed
Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
NCT00562224
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +26 more
- Locations
-
- California Cancer Care Greenbrae, California, United States
- University of Chicago Chicago, Illinois, United States
- Sarah Cannon Research Institue Nashville, Tennessee, United States
- MD Anderson Cancer Center Houston, Texas, United States
NCT00050427
- Conditions
- Breast Diseases, Breast Neoplasms, Neoplasms, +3 more
- Locations
-
Not specified
NCT01043913
- Conditions
- Breast Diseases, Breast Neoplasms, Fatigue, +6 more
- Locations
-
- Faculdade de Medicina do ABC Santo André, São Paulo, Brazil
NCT00377520
- Conditions
- Cancer of Endometrium, Cancer of the Endometrium, Endometrial Cancer, +15 more
- Locations
-
- Gynecologic Oncology Group 215-854-0770 Philadelphia, Pennsylvania, United States
NCT00830973
- Conditions
- Breast Diseases, Breast Neoplasms, Neoplasms, +4 more
- Locations
-
- Robert Epstein Franklin Lakes, New Jersey, United States
Active, Not Recruiting
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
NCT06237920
- Conditions
- Antineoplastics Toxicity, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +10 more
- Locations
-
- Rijnstate Arnhem, Gelderland, Netherlands
- Radboud University Medical Center Nijmegen, Gelderland, Netherlands
- NKI-AVL Amsterdam, North Holland, Netherlands
- Amsterdam UMC (AUMC) Amsterdam, North Holland, Netherlands
Active, Not Recruiting
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT04964934
- Conditions
- Breast Diseases, Breast Neoplasms, ER-Positive HER2-Negative Breast Cancer, +8 more
- Locations
-
- Research Site Phoenix, Arizona, United States
- Research Site Hot Springs, Arkansas, United States
- Research Site Little Rock, Arkansas, United States
- Research Site Long Beach, California, United States
Active, Not Recruiting
Savolitinib vs. Sunitinib in MET-driven PRCC.
NCT03091192
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
- Locations
-
- Research Site La Jolla, California, United States
- Research Site Atlanta, Georgia, United States
- Research Site Chicago, Illinois, United States
- Research Site Iowa City, Iowa, United States
Active, Not Recruiting
TheraSphere With Durvalumab and Tremelimumab for HCC
NCT05063565
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
- Locations
-
- University of Arizona- Banner Health Tucson, Arizona, United States
- University of California San Diego San Diego, California, United States
- University of California San Francisco San Francisco, California, United States
- Georgetown University Washington D.C., District of Columbia, United States